

prIME Points™

- ✓ **Contemporary strategies for treatment of RRMM include the use of new monoclonal antibodies, next generation PIs and IMiDs, and an HDACi**
- ✓ **Important considerations in selection of therapy for RRMM are patient age/fitness, adverse cytogenetics, lines of prior therapy, and response to prior therapy**
- ✓ **Recent randomized III trials support the superiority of using triplets over doublets for fit patients, particularly in high risk disease**
- ✓ **Current trials are exploring how to best use immunotherapies in RRMM including monoclonal antibodies, checkpoint inhibitors, CAR T-cells, ADCs, and BITEs**
- ✓ **Other agents with novel targets in RRMM are also in clinical trials such as a Bcl2 and XPO inhibitor**